HR 4398 · 116th Congress 2019–2021, ended

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

Latest action · Oct 2, 2019 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedSep 19, 2019
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a hard switch or a soft switch. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A follow-on product is a changed, modified, or reformulated version of a manufacturer’s already-approved drug or biological product that still treats the same medical condition.

A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.

A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.

Cosponsors

Members who signed on, in the order they did.

No cosponsors are on file for this measure.

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseJudiciary Committee
Referred Sep 19, 2019
Administrative State, Regulatory Reform, and Antitrust Subcommittee
Referred Oct 2, 2019

Actions 3

Everything that happened, newest first.

  1. Oct 2, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
  2. Sep 19, 2019Introduced in House
  3. Sep 19, 2019Referred to the House Committee on the Judiciary.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1 Section 8

The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 151, September 19, 2019, page H7836.

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 3

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 1416Affordable Prescriptions for Patients Act of 2019Related billJun 28, 2019
HR 2486FUTURE ActRelated billJul 23, 2020
HR 5133Affordable Prescriptions for Patients Through Promoting Competition Act of 2019Related billDec 24, 2020

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.
Short Title(s) as Introduced
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

Subjects

Assigned by the Library of Congress. Policy area: Commerce.

Text 1

Each version as it was printed, newest first.

  1. Sep 19, 2019Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.